Self.co raises €2.56M for accessible allergy testing in Europe

Nearly half of Europeans struggle with allergy misdiagnosis, creating a healthcare gap that costs both patients and systems dearly. This diagnostic challenge has caught the attention of European investors, particularly as personalised healthcare becomes increasingly prioritised across EU markets. Lithuanian startup Self.co has secured €2.56 million in funding to tackle this widespread issue, making allergy testing more accessible to European consumers.

The funding round positions Self.co at the forefront of Europe’s growing digital health movement, where regulatory frameworks like the Medical Device Regulation create both opportunities and compliance requirements that favour well-prepared startups.

Lithuanian startup funding round attracts European venture capital

Iron Wolf Capital led this significant investment, demonstrating the growing confidence in Baltic tech innovation. The Lithuanian VC’s involvement signals a broader trend of regional capital backing local solutions to pan-European problems. Iron Wolf’s portfolio strategy focuses on B2B and healthcare technology, making Self.co a natural fit for their thesis around accessible medical solutions.

“We’re seeing unprecedented demand for at-home diagnostic solutions across Europe, and Self.co’s approach to allergy testing addresses a genuine market need,” noted a representative from the investment team. The funding structure reflects typical European Series A characteristics, with local lead investors bringing both capital and market knowledge essential for navigating Europe’s fragmented healthcare systems.

The investor mix suggests confidence in Self.co’s ability to scale across European markets, where healthcare regulations vary significantly between member states. This regulatory complexity often favours startups that can demonstrate compliance early in their development cycle.

Digital health innovation tackles European allergy crisis

Self.co’s platform addresses a critical gap in European healthcare delivery, where traditional allergy testing often requires lengthy waits and specialist appointments. The company’s solution enables consumers to conduct reliable allergy tests from home, potentially reducing the diagnostic timeline from months to days. This approach particularly resonates in Nordic and Baltic markets, where healthcare digitisation has accelerated post-pandemic.

The startup competes in a growing European market that includes established players like Thriva and emerging digital health platforms. However, Self.co’s specific focus on allergy testing provides clear differentiation in a sector where specialisation often trumps broad-spectrum offerings. Their technology integrates with existing healthcare systems, crucial for adoption in Europe’s diverse medical landscapes.

“Our goal is to make allergy testing as simple as checking your blood pressure at home,” explained the Self.co team regarding their European expansion strategy. The funding will primarily support product development and regulatory approvals across key EU markets, starting with Germany and the Netherlands where digital health adoption rates remain high.

This investment reflects Europe’s broader shift toward preventive healthcare solutions, supported by regulatory frameworks that increasingly favour patient-centric innovation. Self.co’s timing aligns with EU digital health initiatives that prioritise accessible, data-driven medical solutions for common conditions like allergies.